{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:02:53Z","timestamp":1779951773488,"version":"3.53.1"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent type 2 inflammatory disorder that substantially impairs patient quality of life (QoL) through cardinal symptoms of nasal obstruction, olfactory dysfunction, and sleep disturbance, further compounded by frequent comorbidities including asthma and non-steroidal anti-inflammatory drug-exacerbated respiratory disease (NERD). While conventional therapies with intranasal corticosteroids, systemic corticosteroids, and endoscopic sinus surgery remain foundational, their limitations in achieving durable disease control have prompted the emergence of biologic agents targeting key type 2 inflammatory pathways. This narrative review synthesizes evidence from a targeted literature search including randomized controlled trials and complementary real-world studies to evaluate the impact of biologic therapies on patient-reported QoL outcomes in severe CRSwNP. Biologic agents targeting key mediators of type 2 inflammation have consistently demonstrated clinically meaningful improvements in disease-specific QoL, as measured by the Sinonasal Outcome Test-22 (SNOT-22), across nasal, sleep, olfactory, and emotional domains, with consistent benefits regardless of comorbidities or prior surgery. Real-world evidence corroborates trial findings, demonstrating sustained QoL benefits and reduced dependence on systemic corticosteroids and revision surgery. The integration of patient-reported outcome measures into therapeutic decision-making bridges the gap between objective clinical metrics and lived disease burden, informing patient-centered care models. Biologic therapies have redefined success in CRSwNP management by consistently delivering multidimensional, durable improvements in patient-reported QoL, head-to-head comparisons and optimized treatment sequencing warrant further research.<\/jats:p>","DOI":"10.3389\/falgy.2026.1846744","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:18:56Z","timestamp":1779949136000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CRSwNP in the biologics era: evaluating patient-reported quality of life outcomes"],"prefix":"10.3389","volume":"7","author":[{"given":"Tianhui","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zha","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanshen","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surita","family":"Aodeng","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100895","DOI":"10.1016\/j.waojou.2024.100895","article-title":"Management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP): results from a survey among allergists and clinical immunologists of the north-west and center Italy inter-regional sections of SIAAIC and otorhinolaryngologists of national IAR","volume":"17","author":"Bagnasco","year":"2024","journal-title":"World Allergy Organ J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4193\/Rhin22.436","article-title":"Biologicals in severe chronic rhinosinusitis with nasal polyps: translation to clinical practice while waiting for head-to-head studies","volume":"61","author":"Boechat","year":"2023","journal-title":"Rhinology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1599797","DOI":"10.3389\/falgy.2025.1599797","article-title":"The advance on pathophysiological mechanisms of type 2 chronic rhinosinusitis with nasal polyposis","volume":"6","author":"Yang","year":"2025","journal-title":"Front Allergy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1356298","DOI":"10.3389\/fimmu.2024.1356298","article-title":"The interleukin-4\/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps","volume":"15","author":"Bachert","year":"2024","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e70095","DOI":"10.1002\/clt2.70095","article-title":"Characterization of chronic rhinosinusitis patients based on markers of type 2 inflammation: findings from the European CRS outcome registry (CHRINOSOR)","volume":"15","author":"Cavaliere","year":"2025","journal-title":"Clin Transl Allergy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","article-title":"European Position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/00034894241298749","article-title":"Enlarged frontal sinusotomy and chronic rhinosinusitis with nasal polyps: an effective strategy to control the disease","volume":"134","author":"Saccardo","year":"2025","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4193\/Rhin22.344","article-title":"The EUFOREA pocket guide for chronic rhinosinusitis","volume":"61","author":"Hellings","year":"2023","journal-title":"Rhinology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1007\/s12325-024-02984-w","article-title":"Reduced sense of smell in patients with severe chronic rhinosinusitis and its implications for diagnosis and management. A Narrative Review","volume":"41","author":"Soler","year":"2024","journal-title":"Adv Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jaip.2016.04.008","article-title":"Infectious chronic rhinosinusitis","volume":"4","author":"Bose","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4193\/Rhin23.415","article-title":"EPOS2020\/EUFOREA Expert opinion on defining disease states and therapeutic goals in CRSwNP","volume":"62","author":"Fokkens","year":"2024","journal-title":"Rhinology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3390\/ph18101455","article-title":"Optimizing biologic treatment selection in chronic rhinosinusitis with nasal polyps: a network meta-analysis of efficacy and safety across 22 RCTs","volume":"18","author":"Safia","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1002\/clt2.70010","article-title":"Chronic rhinosinusitis with nasal polyps: key considerations in the multidisciplinary team approach","volume":"15","author":"Pfaar","year":"2025","journal-title":"Clin Transl Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/17476348.2023.2181794","article-title":"Mepolizumab for the treatment of chronic rhinosinusitis with nasal polyps in adults","volume":"17","author":"Neposlan","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e12200","DOI":"10.1002\/clt2.12200","article-title":"The burden of chronic rhinosinusitis with nasal polyps and its relation to asthma in Finland","volume":"12","author":"Toppila-Salmi","year":"2022","journal-title":"Clin Transl Allergy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1007\/s00405-024-08790-y","article-title":"The use of biologics in patients suffering from chronic rhinosinusitis with nasal polyps\u2014a 4-year real life observation","volume":"281","author":"Frankenberger","year":"2024","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2025.12515","article-title":"Stapokibart for severe uncontrolled chronic rhinosinusitis with nasal polyps: the CROWNS-2 randomized clinical trial","volume":"334","author":"Shen","year":"2025","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4193\/Rhin22.412","article-title":"Biologic treatment for severe chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis","volume":"61","author":"Kariyawasam","year":"2023","journal-title":"Rhinology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3390\/jcm12041391","article-title":"Molecular and clinical predictors of quality of life in chronic rhinosinusitis with nasal polyps","volume":"12","author":"Brunet","year":"2023","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/19458924241274501","article-title":"Association between smell loss, disease burden, and dupilumab efficacy in chronic rhinosinusitis with nasal polyps","volume":"39","author":"Soler","year":"2025","journal-title":"Am J Rhinol Allergy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1002\/lary.31557","article-title":"Quality of life in symptomatic septal perforation","volume":"134","author":"Alegre Edo","year":"2024","journal-title":"Laryngoscope"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3390\/jcm13061699","article-title":"Comparison of long-term postoperative outcomes of the subtypes of chronic rhinosinusitis with nasal polyps","volume":"13","author":"Lee","year":"2024","journal-title":"J Clin Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/alr.22963","article-title":"Omalizumab and quality of life in nasal polyps: a post hoc analysis","volume":"12","author":"Han","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00408-023-00603-z","article-title":"Prevalence and severity distribution of type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis","volume":"201","author":"Khan","year":"2023","journal-title":"Lung"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/jpm12071096","article-title":"Management of patients with severe asthma and chronic rhinosinusitis with nasal polyps: a multidisciplinary shared approach","volume":"12","author":"Seccia","year":"2022","journal-title":"J Pers Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"01","DOI":"10.33545\/26649225.2023.v5.i1a.7","article-title":"Medical condition: persistent rhinosinusitis accompanied by nasal polyps and asthma","volume":"5","author":"George","year":"2023","journal-title":"Int J Otolaryngol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/sinusitis9020017","article-title":"Main findings from retrospective studies on the comorbidity of asthma and sinusitis and their implications for clinical practice","volume":"9","author":"Finck","year":"2025","journal-title":"Sinusitis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin25.901","article-title":"Advancing the research on management of global airway disease: insights from a post hoc analysis","volume":"63","author":"Toppila-Salmi","year":"2025","journal-title":"Rhinology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.anai.2023.06.017","article-title":"Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth","volume":"131","author":"Supron","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/19458924241298817","article-title":"Dupilumab treatment for aspirin-exacerbated respiratory disease in a real-world setting: impact on quality of life and healthcare utilization","volume":"39","author":"Mullur","year":"2025","journal-title":"Am J Rhinol Allergy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1159\/000522255","article-title":"Component-Resolved diagnosis for endotyping patients with chronic rhinosinusitis with nasal polyps","volume":"183","author":"Puxeddu","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00405-020-06418-5","article-title":"Differences in men and women suffering from CRSwNP and AERD in quality of life","volume":"278","author":"Bartosik","year":"2021","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/19458924241287959","article-title":"Practice patterns of biologics prescriptions and surgery in chronic rhinosinusitis with nasal polyps","volume":"39","author":"Almarri","year":"2025","journal-title":"Am J Rhinol Allergy"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2407523","DOI":"10.1080\/07853890.2024.2407523","article-title":"Improvement in health-related quality of life questionnaires with biologic treatment in severe asthma and comorbid chronic rhinosinusitis with or without nasal polyposis: a real-life experience","volume":"56","author":"Santus","year":"2024","journal-title":"Ann Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin24.090","article-title":"Outcome measures for chronic rhinosinusitis with nasal polyps","volume":"62","author":"Sedaghat","year":"2024","journal-title":"Rhinology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/alr.22028","article-title":"Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis","volume":"7","author":"Chowdhury","year":"2017","journal-title":"Int Forum Allergy Rhinol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/lary.25318","article-title":"The predictive value of the preoperative sinonasal outcome test-22 score in patients undergoing endoscopic sinus surgery for chronic rhinosinusitis","volume":"125","author":"Hopkins","year":"2015","journal-title":"Laryngoscope"},{"key":"B41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4193\/Rhino15.284","article-title":"Using postoperative SNOT-22 to help predict the probability of revision sinus surgery","volume":"54","author":"Rudmik","year":"2016","journal-title":"Rhinology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/alr.23285","article-title":"Chinese Adaptation and validation of the chronic rhinosinusitis-patient-reported outcome: assessment of health-related quality-of-life","volume":"14","author":"Chen","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.4193\/Rhin21.282","article-title":"Patient-reported chronic rhinosinusitis disease control is a valid measure of disease burden","volume":"59","author":"Phillips","year":"2021","journal-title":"Rhinology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4193\/Rhin18.122","article-title":"Responsiveness and minimal clinically important difference for the EQ-5D in chronic rhinosinusitis","volume":"57","author":"Hoehle","year":"2019","journal-title":"Rhinology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1007\/s00405-025-09446-1","article-title":"Predictive modeling for score translation among patient-reported outcome measures in chronic rhinosinusitis with nasal polyps: a cross-sectional study","volume":"282","author":"Garc\u00eda-Fern\u00e1ndez","year":"2025","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e87674","DOI":"10.7759\/cureus.87674","article-title":"The efficacy and safety of intranasal corticosteroids in chronic rhinosinusitis: a systematic review","volume":"17","author":"Mawkili","year":"2025","journal-title":"Cureus"},{"key":"B47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.23736\/S0031-0808.24.05200-5","article-title":"Budesonide aqueous nasal spray: an updated review in managing chronic rhinosinusitis with nasal polyps","volume":"66","author":"Ciprandi","year":"2024","journal-title":"Panminerva Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2500\/aap.2025.46.250050","article-title":"The burden of systemic corticosteroids in patients with chronic rhinosinusitis with nasal polyps","volume":"46","author":"Peters","year":"2025","journal-title":"Allergy Asthma Proc"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2240511","DOI":"10.1080\/20018525.2023.2240511","article-title":"Systemic corticosteroids in treatment of chronic rhinosinusitis-A systematic review","volume":"10","author":"Tamene","year":"2023","journal-title":"Eur Clin Respir J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1573764","DOI":"10.3389\/falgy.2025.1573764","article-title":"Efficacy and limitations of systemic corticosteroids in patients with CRSwNP compared to alternative therapies with monoclonal antibodies: real-life of 101 patients from the lazio region, Italy","volume":"6","author":"Anastasi","year":"2025","journal-title":"Front Allergy"},{"key":"B52","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/19458924251366569","article-title":"Biologics and surgery in chronic rhinosinusitis with nasal polyps: a comparative outcomes analysis","volume":"39","author":"Narendran","year":"2025","journal-title":"Am J Rhinol Allergy"},{"key":"B53","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/coa.14331","article-title":"Exploring predictors of post-surgical health-related quality of life and revision surgery in patients with chronic rhinosinusitis with nasal polyps: a cohort study","volume":"50","author":"den Heijer","year":"2025","journal-title":"Clin Otolaryngol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/alr.23594","article-title":"Relevance of the LOEM classification in chronic rhinosinusitis management: a retrospective analysis of surgical outcomes","volume":"15","author":"Martin-Jimenez","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1111\/all.15222","article-title":"Dupilumab improves health-related quality of life in severe chronic rhinosinusitis with nasal polyps","volume":"77","author":"Lee","year":"2022","journal-title":"Allergy"},{"key":"B56","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2147\/JAA.S355391","article-title":"Rapid and continuing improvements in nasal symptoms with dupilumab in patients with severe CRSwNP","volume":"15","author":"Bachert","year":"2022","journal-title":"J Asthma Allergy"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/alr.22780","article-title":"Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"11","author":"Hopkins","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/alr.22944","article-title":"Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps","volume":"12","author":"Hellings","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/JAA.S357393","article-title":"Clinical efficacy among patients with chronic rhinosinusitis with nasal polyps and clinical features of obstructive lung disease: post hoc analysis of the phase III SINUS-24 and SINUS-52 studies","volume":"16","author":"Maspero","year":"2023","journal-title":"J Asthma Allergy"},{"key":"B60","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.2147\/DDDT.S226575","article-title":"Chronic rhinosinusitis with nasal polyps: targeting IgE with anti-IgE omalizumab therapy","volume":"14","author":"Kariyawasam","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"B62","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/19458924211030486","article-title":"Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis","volume":"36","author":"Damask","year":"2022","journal-title":"Am J Rhinol Allergy"},{"key":"B63","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.anai.2023.11.001","article-title":"Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status","volume":"132","author":"Gevaert","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/alr.23322","article-title":"Omalizumab improves sleep and health status for patients with chronic rhinosinusitis with nasal polyps: an analysis of randomized clinical trials","volume":"14","author":"Meltzer","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41687-023-00543-5","article-title":"Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study","volume":"7","author":"Fokkens","year":"2023","journal-title":"J Patient Rep Outcomes"},{"key":"B67","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/alr.23219","article-title":"Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: sYNAPSE 24-week treatment-free follow-up","volume":"14","author":"Desrosiers","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"320","DOI":"10.4193\/Rhin22.416","article-title":"Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE","volume":"62","author":"Mullol","year":"2024","journal-title":"Rhinology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA Expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"419","DOI":"10.18176\/jiaci.0939","article-title":"Improvement in smell using monoclonal antibodies among patients with chronic rhinosinusitis with nasal polyps: a systematic review","volume":"33","author":"Barroso","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1111\/all.16189","article-title":"Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis","volume":"79","author":"Bachert","year":"2024","journal-title":"Allergy"},{"key":"B74","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"B75","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1016\/j.jaip.2023.09.007","article-title":"Another therapy for chronic rhinosinusitis with nasal polyps","volume":"11","author":"Dokmeci","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B76","doi-asserted-by":"publisher","first-page":"250186","DOI":"10.1183\/16000617.0186-2025","article-title":"Efficacy of biologic agents in patients with comorbid asthma and chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials","volume":"35","author":"Kyriakopoulos","year":"2026","journal-title":"Eur Respir Rev"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2147\/JAA.S413064","article-title":"Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR","volume":"16","author":"Laidlaw","year":"2023","journal-title":"J Asthma Allergy"},{"key":"B79","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12325-024-03006-5","article-title":"Effect of tezepelumab on sino-nasal outcome test (SNOT)-22 domain and symptom-specific scores in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps","volume":"42","author":"Jacobs","year":"2025","journal-title":"Adv Ther"},{"key":"B80","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5415\/apallergy.0000000000000156","article-title":"Anti-IL-4Ralpha monoclonal antibody (CM310) in patients with chronic rhinosinusitis with nasal polyps (CROWNS-2): rationale and design of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"14","author":"Shen","year":"2024","journal-title":"Asia Pac Allergy"},{"key":"B81","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4193\/Rhin24.284","article-title":"Responders to biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: a multicentric observational real-life study","volume":"63","author":"Mortuaire","year":"2025","journal-title":"Rhinology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4193\/Rhin25.157","article-title":"Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS outcome registry (CHRINOSOR)","volume":"63","author":"Mortuaire","year":"2025","journal-title":"Rhinology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e70133","DOI":"10.1002\/lio2.70133","article-title":"FDA-approved biologics for CRSwNP: a five-year analysis of the FDA adverse event reporting system","volume":"10","author":"Duggal","year":"2025","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/all.14422","article-title":"ARIA Digital anamorphosis: digital transformation of health and care in airway diseases from research to practice","volume":"76","author":"Bousquet","year":"2021","journal-title":"Allergy"},{"key":"B85","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1001\/jamainternmed.2015.7712","article-title":"Effectiveness of remote patient monitoring after discharge of hospitalized patients with heart failure: the better effectiveness after transition\u2014heart failure (BEAT-HF) randomized clinical trial","volume":"176","author":"Ong","year":"2016","journal-title":"JAMA Intern Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e47179","DOI":"10.2196\/47179","article-title":"Remote symptom monitoring with ecological momentary computerized adaptive testing: pilot cohort study of a platform for frequent, low-burden, and personalized patient-reported outcome measures","volume":"25","author":"Harrison","year":"2023","journal-title":"J Med Internet Res"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/IPRP.S492422","article-title":"Developing a prototype machine learning model to predict quality of life measures in people living with HIV","volume":"14","author":"Mercadal-Orfila","year":"2025","journal-title":"Integr Pharm Res Pract"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e70300","DOI":"10.1002\/lio2.70300","article-title":"Predictive value of blood eosinophil ratio for risk stratification in patients with eosinophilic chronic rhinosinusitis with nasal polyps","volume":"10","author":"Zuo","year":"2025","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1007\/s00405-024-08574-4","article-title":"The value of biomarkers in the therapy of CRSwNP with biologicals-a long-term follow-up of dupilumab therapy","volume":"281","author":"Sarnoch","year":"2024","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/ACI.0000000000000799","article-title":"Clinical and biological markers in disease and biologics to treat chronic rhinosinusitis","volume":"22","author":"Guo","year":"2022","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1846744\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:18:57Z","timestamp":1779949137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1846744\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":90,"alternative-id":["10.3389\/falgy.2026.1846744"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1846744","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1846744"}}